Journal article icon

Journal article

Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): A prospectively stratified randomised trial

Abstract:

Background: Therapeutic antibodies targeting EGFR have activity in advanced colorectal cancer, but results from clinical trials are inconsistent and the population in which most benefit is derived is uncertain. Our aim was to assess the addition of panitumumab to irinotecan in pretreated advanced colorectal cancer. Methods: In this open-label, randomised trial, we enrolled patients who had advanced colorectal cancer progressing after fluoropyrimidine treatment with or without oxaliplatin from...

Expand abstract

Actions


Access Document


Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Oncology
Role:
Author
Expand authors...
Journal:
Lancet Oncology
Volume:
14
Issue:
8
Pages:
749-759
Publication date:
2013-07-01
DOI:
EISSN:
1474-5488
ISSN:
1470-2045
Source identifiers:
412058
Language:
English
Pubs id:
pubs:412058
UUID:
uuid:121b0ad2-3228-47d9-b8ba-89ba4d86be17
Local pid:
pubs:412058
Deposit date:
2013-11-16

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP